Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214773 · ClinicalTrials.gov registry record
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 237
- Enrollment target
NCT00214773: Completed study, sponsored by BioMarin Pharmaceutical.
NCT00214773 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 237 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00214773 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 237 participants
- Enrollment target
Study Summary
The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2005-07 |
| Est. Completion | 2020-05-01 |
What the finished NCT00214773 record still lists
NCT00214773 is an observational study that tracks outcomes without assigning an intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00214773 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00214773 about?
NCT00214773 is a clinical study titled "Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)". The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing informatio...
What is the current status of trial NCT00214773?
This trial is currently completed. The enrollment target is 237 participants. The study started on 2005-07. Estimated completion is 2020-05-01.
Who is sponsoring clinical trial NCT00214773?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05974176 · 237 participants · NA
Considering Racial and Acculturation Stress in Addressing Trauma
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia